The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

Are you one of these people who loathes spending time outdoors at dusk as the weather warms and mosquitoes start biting?

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

While a cocktail may be the very least appealing thing to you in the throes of a migraine attack, a "migraine cocktail" could be the very thing that helps break it. Learn what this rescue therapy ...

No new safety findings were observed. The most common treatment-emergent adverse events (>10 percent) occurring more ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 202 ...